Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

The Phase IV THRIVE trial found that 60% of adult migraine participants treated with eptinezumab reported being "much improved" or "very much improved" on the primary endpoint. The prospective clinical data support the treatment's effectiveness in migraine patients and could strengthen its commercial and clinical positioning, although the excerpt provides no safety data, comparator results, or financial impact.